US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

43.40

-0.0545-0.13%

Post-market: 43.28-0.1210-0.28%16:15 EDT

Volume:2K

Turnover:104.68K

Market Cap:120.53M

PE:- -

High:43.93

Open:43.78

Low:43.20

Close:43.46

52wk High:48.78

52wk Low:29.31

Shares:2.78M

Float Shares:2.78M

Volume Ratio:1.11

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Travere Therapeutics SVP, Chief Accounting Officer Sandra Calvin Disposes of $335,983 in Common Shares

Guardant Health Director Tariq Musa Sells 116 Common Shares for $20,300

Ultragenyx confirms FDA approval of Fayuvi

FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A

US Health Secretary Kennedy Jr. Adds Eight New Members to Key Health Committee

Guardant Health on Track for Record High Close

Nuvation Bio announces FDA approval of sNDA for Ibtrozi

Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes

Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial

Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says

MT Newswires Live

ASX biotech expands diagnostics portfolio after FDA approval

Morning Star AU

Cogent Biosciences reports FDA acceptance of bezuclastinib new drug application

Cogent Biosciences, - FDA States no Advisory Committee Planned and no Review Issues Identified

THOMSON REUTERS

Cogent Biosciences Announces FDA Acceptance of New Drug Application (Nda) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (Advsm)

THOMSON REUTERS

Cogent Biosciences, - FDA Accepts Nda for Bezuclastinib in Advsm with Pdufa Date June 29, 2027

THOMSON REUTERS

Press Release: Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

Barclays downgrades Scholar Rock on valuation after FDA approval

Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20

LivaNova Director Francesco Bianchi Sells 3,500 Shares for $273,032.20

Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/LFSC/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":43.401,"timestamp":1790971200000,"preClose":43.4555,"halted":0,"volume":2399,"hourTrading":{"tag":"盘后","latestPrice":43.28,"preClose":43.401,"latestTime":"16:15 EDT","volume":10,"amount":433.284,"timestamp":1790972100316,"change":-0.121,"changeRate":-0.002788,"amplitude":0.002788},"delay":0,"changeRate":-0.001254156550954363,"floatShares":2777035,"shares":2777035,"eps":0,"marketStatus":"Post-Mkt","change":-0.0545,"latestTime":"10-02 17:50:35 EDT","open":43.775,"high":43.93,"low":43.195,"amount":104678,"amplitude":0.016914,"askPrice":65.38,"askSize":200,"bidPrice":42.75,"bidSize":12,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790985600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":43.4555,"sharesOutstanding":2657035,"nav":44.42,"aum":123355894.7,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":43.28,"preClose":43.401,"latestTime":"16:15 EDT","volume":10,"amount":433.284,"timestamp":1790972100316,"change":-0.121,"changeRate":-0.002788,"amplitude":0.002788},"volumeRatio":1.110648},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2777035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.110648,"shares":2777035,"dividePrice":0,"high":43.93,"amplitude":0.016914,"preClose":43.4555,"low":43.195,"week52Low":29.3143,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":43.401,"committee":-0.886792,"eps":0,"divideRate":0,"volume":2399,"delay":0,"ttmEps":0,"open":43.775,"prevYearClose":36.6147,"prevWeekClose":44.4638,"prevMonthClose":44.5697,"prevQuarterClose":44.5697,"fiveDayClose":44.4638,"twentyDayClose":46.1466,"sixtyDayClose":47.375},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668916520","title":"Travere Therapeutics SVP, Chief Accounting Officer Sandra Calvin Disposes of $335,983 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2668916520","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668916520?lang=en_us&edition=fundamental","pubTime":"2026-09-18 09:30","pubTimestamp":1789695001,"startTime":"0","endTime":"0","summary":"Travere Therapeutics SVP, Chief Accounting Officer Sandra Calvin disposes of $335,983 in common sharesSandra Calvin, SVP and chief accounting officer, sold 5,375 Travere Therapeutics common shares on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDLbDJpyV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Travere Therapeutics SVP, Chief Accounting Officer Sandra Calvin Disposes of $335,983 in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4139","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668976309","title":"Guardant Health Director Tariq Musa Sells 116 Common Shares for $20,300","url":"https://stock-news.laohu8.com/highlight/detail?id=2668976309","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668976309?lang=en_us&edition=fundamental","pubTime":"2026-09-18 05:10","pubTimestamp":1789679402,"startTime":"0","endTime":"0","summary":"Guardant Health director Tariq Musa sells 116 common shares for $20,300Guardant Health director Tariq Musa sold 116 common shares on Sep. 16, 2026 at USD 175.Directly held common stock fell to 11,449 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL5VHhJ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Director Tariq Musa Sells 116 Common Shares for $20,300","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","LU0889565916.HKD","LU0109394709.USD","GNOM","GNMX","EKG","BK4551","LFSC","BK4535","FFOX","GH","HELX","BK4588","PTH","LU0320765992.SGD","GDOC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994030","title":"Ultragenyx confirms FDA approval of Fayuvi","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994030","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994030?lang=en_us&edition=fundamental","pubTime":"2026-09-18 03:55","pubTimestamp":1789674924,"startTime":"0","endTime":"0","summary":"Ultragenyx (RARE) announced that the U.S. FDA granted standard full approval of Fayuvi, also known as UX111, for the treatment of pediatric patient...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-confirms-fda-approval-of-fayuvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-confirms-fda-approval-of-fayuvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RSPH","MEDI","BBP","SYNB","TBXU","IYH","BMED","IDNA","GNMX","GDOC","FRTY","MRNY","PSCH","BK4139","LABU","RARE","TECB","XLVX","BK4585","NVIB","MRNX","IBB","LFSC","BK4588","PINK","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668991067","title":"FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A","url":"https://stock-news.laohu8.com/highlight/detail?id=2668991067","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668991067?lang=en_us&edition=fundamental","pubTime":"2026-09-18 02:35","pubTimestamp":1789670130,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration approved Fayuvi, which it calls “the first treatment for pediatric patients with mucopolysaccharidosis type I...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-approves-ultragenyx-gene-therapy-for-sanfilippo-syndrome-type-a-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-approves-ultragenyx-gene-therapy-for-sanfilippo-syndrome-type-a-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBBQ","CNCR","SYNB","IBB","LABU","BK4585","TBXU","LFSC","BK4588","GNOM","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668995985","title":"US Health Secretary Kennedy Jr. Adds Eight New Members to Key Health Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2668995985","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668995985?lang=en_us&edition=fundamental","pubTime":"2026-09-17 23:20","pubTimestamp":1789658440,"startTime":"0","endTime":"0","summary":"UPDATE 6-US Health Secretary Kennedy Jr. adds eight new members to key health committeeSept 17 (Reuters)-US Health Secretary Robert F. Kennedy Jr. on Thursday named eight new members to the advisory p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nL4N4591AI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","GDOC","LU0109394709.USD","PTH","BK4551","BK4588","LFSC","BK4196","LU0889565916.HKD","GH","HELX","LU0320765992.SGD","EKG","BK4585","FFOX","GNMX","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668998049","title":"Guardant Health on Track for Record High Close","url":"https://stock-news.laohu8.com/highlight/detail?id=2668998049","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668998049?lang=en_us&edition=fundamental","pubTime":"2026-09-17 22:16","pubTimestamp":1789654560,"startTime":"0","endTime":"0","summary":"Guardant Health, Inc.  is currently at $180.24, up $5.34 or 3.05%--Would be new all-time closing high --Would be the first new record closing high since Feb. 12, 2021, when it closed at $179.10--On pace for largest percent increase since Sept. 15, 2026, when it rose 4.65%--Currently up three of the past four days--Up 13.34% month-to-date--Up 76.46% year-to-date--Up 206.52% from 52 weeks ago , when it closed at $58.80--Would be a new 52-week closing high--Up 212.53% from its 52-week closing low of $57.67 on Sept. 24, 2025--Traded as high as $181.50; new all-time intraday high --Up 3.77% at today's intraday highAll data as of 10:14:03 AM ETSource: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Guardant Health on Track for Record High Close","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","BK4588","BK4535","GDOC","FFOX","LU0889565916.HKD","PTH","GNMX","HELX","LU0109394709.USD","LU0320765992.SGD","BK4196","BK4585","BK4551","GNOM","EKG","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668996120","title":"Nuvation Bio announces FDA approval of sNDA for Ibtrozi","url":"https://stock-news.laohu8.com/highlight/detail?id=2668996120","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668996120?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:35","pubTimestamp":1789644932,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) announced that the U.S. FDA has approved a supplemental New Drug Application for Ibtrozi, a ROS1 inhibitor approved for the tre...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-announces-fda-approval-of-snda-for-ibtrozi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-announces-fda-approval-of-snda-for-ibtrozi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PINK","IEIH","RSPH","IDNA","LABU","MRNX","GNMX","NVIB","BK4007","TECB","MEDI","FRTY","SYNB","XLVX","PSCH","BK4585","NUVB","GDOC","MRNY","BMED","BBP","LFSC","IBB","TBXU","IYH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668963474","title":"Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2668963474","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668963474?lang=en_us&edition=fundamental","pubTime":"2026-09-17 17:30","pubTimestamp":1789637420,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced that theFDA approved Kerendia to reduce urinary albumin-to-creatinine ratio, which is expected to reduce the risk of sustai...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-receives-fda-approval-for-kerendia-for-ckd-with-type-1-diabetes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-receives-fda-approval-for-kerendia-for-ckd-with-type-1-diabetes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RSPH","BK4588","BK4007","LFSC","GNMX","IBB","TECB","PINK","PSCH","XLVX","SYNB","TBXU","BK4585","GDOC","MRNX","BAYRY","FRTY","BMED","NVIB","MRNY","IDNA","IYH","IEIH","MEDI","LABU","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668936994","title":"Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2668936994","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668936994?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:35","pubTimestamp":1789594520,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced topline results from ELPIS II, its Phase 2b clinical trial evaluating its investigational stem cell therapy laromestroc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeverons-laromestrocel-did-not-meet-primary-endpoint-in-phase-2b-hlhs-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeverons-laromestrocel-did-not-meet-primary-endpoint-in-phase-2b-hlhs-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","BK4588","IDNA","MEDX","BK4585","NVIB","SYNB","IBB","GNOM","GDOC","HYLG","TBXU","IBBQ","CNCR","LFSC","LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667062145","title":"Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2667062145","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667062145?lang=en_us&edition=fundamental","pubTime":"2026-09-16 03:02","pubTimestamp":1789498945,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) stands to benefit from AstraZeneca's (AZN) failed Serena-4 trial because the result preserves the biomarker-driven monitoring approach supporting potential demand for its Guardant","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU2237443622.USD","LU2237443382.USD","LU2417539215.USD","AZN","LU2089984988.USD","EKG","BK4196","HELX","LU0320765992.SGD","LU0889565916.HKD","LU0029864427.USD","LU0310800379.SGD","LU0128525929.USD","LU2462157665.USD","LU0289739699.SGD","BK4568","BK4007","LU0432979614.USD","LU0708994859.HKD","LU2237443549.SGD","LU2237443895.HKD","BK4535","BK4551","FFOX","GDOC","IE00B3T34201.USD","GH","GNMX","LU2237443978.SGD","LU2236285917.USD","LU2237443465.HKD","LU1267930573.SGD","LU0109394709.USD","LFSC","AZNH","BK4588","LU2468319806.SGD","LU1829250122.USD","LU0058720904.USD","PTH","LU2456880835.USD","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667671746","title":"ASX biotech expands diagnostics portfolio after FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2667671746","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667671746?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:00","pubTimestamp":1789488000,"startTime":"0","endTime":"0","summary":"Telix Pharmaceutical’s (ASX.TLX) Pixclara becomes the first positron emission tomography, or PET, imaging agent for glioma brain cancer to receive approval from the US Food and Drug Administration.Why","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/stocks/asx-biotech-expands-diagnostics-portfolio-after-fda-approval","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/stocks/asx-biotech-expands-diagnostics-portfolio-after-fda-approval","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["IDNA","NVIB","PSCH","TECB","MEDI","BK4585","BMED","XBIX","IEIH","IYH","MRNX","MRNY","SYNB","GNMX","IBB","BBP","LABU","RSPH","BK4588","GDOC","TBXU","FRTY","PINK","LFSC","XLVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667264291","title":"Cogent Biosciences reports FDA acceptance of bezuclastinib new drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2667264291","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667264291?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:10","pubTimestamp":1789474252,"startTime":"0","endTime":"0","summary":"Cogent Biosciences (COGT) announced that the FDA has accepted its new drug application for bezuclastinib in patients with Advanced Systemic Mastocy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cogent-biosciences-reports-fda-acceptance-of-bezuclastinib-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cogent-biosciences-reports-fda-acceptance-of-bezuclastinib-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CANC","BK4588","BK4139","LU1670628061.USD","BK4532","LABU","CCOI","LU1670627923.USD","LFSC","BK4505","COGT","BK4585","BK4089"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667644495","title":"Cogent Biosciences, - FDA States no Advisory Committee Planned and no Review Issues Identified","url":"https://stock-news.laohu8.com/highlight/detail?id=2667644495","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667644495?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:00","pubTimestamp":1789473602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA54B85Z:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COGT","CANC","BK4139","BK4505","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667644490","title":"Cogent Biosciences Announces FDA Acceptance of New Drug Application (Nda) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (Advsm)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667644490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667644490?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:00","pubTimestamp":1789473602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA54B85Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","COGT","LFSC","BK4505","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667444456","title":"Cogent Biosciences, - FDA Accepts Nda for Bezuclastinib in Advsm with Pdufa Date June 29, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667444456","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667444456?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:00","pubTimestamp":1789473602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA54B85Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CANC","LFSC","BK4505","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667444786","title":"Press Release: Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667444786","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667444786?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:00","pubTimestamp":1789473600,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (\"Legend Biotech\" or the \"Company\"), a global leader in cell therapy, today announced that its Board of ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","GNOM","MEDI","CANC","BK4232","MEMS","CNCR","IBBQ","XBI","BK4022","FBT","BK4588","LEGN","TBXU","SYNB","IBB","LFSC","R","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667643557","title":"Barclays downgrades Scholar Rock on valuation after FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2667643557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667643557?lang=en_us&edition=fundamental","pubTime":"2026-09-15 17:10","pubTimestamp":1789463419,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout downgraded Scholar Rock (SRRK) to Equal Weight from Overweight with a price target of $58, up from $55. The approval ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/barclays-downgrades-scholar-rock-on-valuation-after-fda-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/barclays-downgrades-scholar-rock-on-valuation-after-fda-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","XLVX","TACU","NVIB","BMED","LFSC","IYH","LABU","FRTY","BBP","TSPA","MEDI","IEIH","TECB","GNMX","CDIG","PINK","MRNY","IBB","SYNB","GDOC","IDNA","RSPH","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667569983","title":"Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2667569983","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667569983?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:12","pubTimestamp":1789423938,"startTime":"0","endTime":"0","summary":"Guardant Health CIO Kumud Kalia disposes of 4,000 common shares worth $632,193.20Guardant Health Chief Information Officer Kumud Kalia sold 4,000 common shares on Sept. 11, 2026.The sale price was USD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL3DVtS3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","LU0320765992.SGD","BK4585","EKG","FFOX","GDOC","BK4196","LU0109394709.USD","GNOM","GNMX","LU0889565916.HKD","PTH","HELX","BK4588","GH","BK4535","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695583","title":"LivaNova Director Francesco Bianchi Sells 3,500 Shares for $273,032.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695583","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695583?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:24","pubTimestamp":1789417453,"startTime":"0","endTime":"0","summary":"LivaNova director Francesco Bianchi sells 3,500 shares for $273,032.20LivaNova director Francesco Bianchi sold 3,500 ordinary shares on Sep. 10, 2026 at USD 78.01 per share.Direct holdings fell to 4,4","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL6ygSL8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"LivaNova Director Francesco Bianchi Sells 3,500 Shares for $273,032.20","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LFSC","BK4082","LU2065171311.SGD","LU2065171402.SGD","LU2065169927.USD","LIVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667087693","title":"Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667087693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667087693?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:07","pubTimestamp":1789416443,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nFWN4560HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","FFOX","BK4588","BK4551","BK4196","EKG","GNOM","LU0889565916.HKD","LU0109394709.USD","GH","BK4585","GNMX","BK4535","HELX","LU0320765992.SGD","GDOC","PTH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}